EUpALS would like to invite you for its upcoming webinar on Nov 10th - 10h30-12h CET! We welcome speakers from our industry partners Ferrer, VectorY and @Regeneron , who will give an update on their work in clinical development. Register now! #ALS #TogetherWeAreStronger #MND

EUpALS partners in the European #Hereditary Project, they have launched a new citizen science questionnaire to explore how people understand health-related information and to identify ways to make medical terms clearer and easier to understand. hereditary-project.eu/do-med…

We had the pleasure to welcome Robert-Jan van Son (Orphan Now, repr Ferrer Belgium) in the offices of EUpALS and ALS Liga België - Ligue SLA Belgique. We enjoyed the informative catch-up and look forward to continue our battle against ALS together #ALS #MND #TogetherWeAreStronger

EUpALS attended the iMND meeting 2026 in Rotterdam. At this international scientific gathering investigators share their knowledge on how organoids contribute to further understanding the ALS disease mechanism and develop potential therapies. #iMND2026 #ALS #MND #ALSResearch

VectorY expands the trial size of the PIONEER-ALS Phase 1/2 clinical trial from 12 to 36 participants. This broadens the evaluation of VTx-002 and will help in the understanding of how it may address the underlying pathology of ALS Read more below #ALS #TogetherWeAreStrong #MND

BREAKING NEWS: EUpALS Industry Partners @ionispharma and @OtsukaUS announce positive topline results from the Phase 3 FUSION trial with ulefnersen in FUS-ALS. Read the attached press release. Another example that ALS is a treatable disease !!! #ALS #EUpALS #TogetherWeAreStrong

The EUpALS Newsletter Autumn 2026 edition is out. Read this and previous issues at als.eu/news/ Don't miss future ones by signing up via als.eu

From 5-12 October Tom Horton will be undertaking a paddleboarding expedition Greek Islands Paddle to Cure ALS in honor of his mother Anastasia Kaliopi Daoutis Horton, who passed away in 2005 due to ALS. The EUpALS team wishes them the best of luck! Info: alshellas.gr/one-journey-two…

BREAKING EUpALS Industry Partner @Novartis shares a community update on the discontinuation of the ASTRALS Phase 2 trial with VHB937 in people with #ALS/#MND. Please, read the attached communication. #EUpALS #TogetherWeAreStrong

The ERN EURO-NMD published the ALS Patient Journey. See ern-euro-nmd.eu/educational.… and attached. The ALS Patient Journey is an important educational instrument for patients seeking support, clinicians striving for greater insight, and researchers pursuing innovative solutions.

Satellite to #ENCALS 2026 in Madrid, EUpALS organized its Annual General Meeting. We informed our stakeholders about EUpALS activities, governance, and EUpALS partnership in EU Horizon projects #real4reg and @Hereditary_EU Project . Thank you all for your attendance!

Satellite to #ENCALS 2026 Madrid, EUpALS organized its Round Table on 'Inclusion/exclusion criteria in ALS clinical trials'. Thank you EUpALS Patients and Carers Expert Board, EUpALS Scientific Expert Board, EUpALS Industry Partners and EMA for the interactive disussion.

EUpALS Industry Partners @ferrerforgood and @PrileniaTx announce enrollment of the first European participant in the PREVAiLS Phase 3 study with pridopidine in ALS. Read the attached press release. #EUpALS #TogetherWeAreStrong

EUpALS is partner in EU Horizon project real4reg.eu/. End 2026 we organise a Final Symposium, including a patients dedicated session. Patients and patient organisations can help decide the theme. Scan the QR code or go to mentimeter.com with code 5196 8269.

EUpALS Industry Partner @Corcept announces an update of the Phase 2 DAZALS study of Dazucorilant, demonstrating two-year overall survival benefit in patients with ALS. Read the attached press release. #EUpALS #Togetherwearestrong

EUpALS Industry Partner @Novartis announces completion of enrollment of Phase 2 ASTRALS trial with VHB937 in ALS. Read attached Community Statement about the number of patients enrolled, how VHB937 works, and expected time when the community will hear next update from Novartis.

EUpALS is partner in EU project @Real4Reg, in which ALS is a use case. Join our online Patients Workshop on 13 April 2026 (15:00-16:30 CET) entitled “Real-World Data and Patients: Breaking the Ice” by registering for free at forms.gle/jSdj18c7kgfd41Gt7

EUpALS Industry Partners @ferrerforgood and @PrileniaTx jointly announce first enrollment in the PREVAiLS Phase 3 study of pridopidine in people with rapidly progressive ALS early in their disease course. Recruitment at additional sites including EU is expected in coming weeks.

The EUpALS Newsletter Spring 2026 edition is out. Read this and previous issues at als.eu/news/ Don't miss future ones by signing up via als.eu/

EUpALS brings to your attention the questionnaire for people with ALS and their carers, developed by the ERN-NMD. The survey in multiple European languages can be found at ec.europa.eu/eusurvey/runner… Please distribute to your pALS and cALS.